These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 23135095)

  • 1. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
    Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
    J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B; Kerr H
    Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
    Li JR; Yang CR; Cheng CL; Ho HC; Chiu KY; Su CK; Chen WM; Wang SS; Chen CS; Yang CK; Ou YC
    Support Care Cancer; 2013 Mar; 21(3):907-11. PubMed ID: 23262811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Reilly LM; Gerami P; Guitart J
    Ann Oncol; 2008 Nov; 19(11):1955-61. PubMed ID: 18550575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
    Poprach A; Pavlik T; Melichar B; Puzanov I; Dusek L; Bortlicek Z; Vyzula R; Abrahamova J; Buchler T;
    Ann Oncol; 2012 Dec; 23(12):3137-3143. PubMed ID: 22700990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
    Massey PR; Okman JS; Wilkerson J; Cowen EW
    Support Care Cancer; 2015 Jun; 23(6):1827-35. PubMed ID: 25471178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
    Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
    J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lacouture ME; Wu S; Robert C; Atkins MB; Kong HH; Guitart J; Garbe C; Hauschild A; Puzanov I; Alexandrescu DT; Anderson RT; Wood L; Dutcher JP
    Oncologist; 2008 Sep; 13(9):1001-11. PubMed ID: 18779536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
    Ochi M; Kamoshida T; Ohkawara A; Ohkawara H; Kakinoki N; Hirai S; Yanaka A
    World J Gastroenterol; 2018 Jul; 24(28):3155-3162. PubMed ID: 30065561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
    Teo YL; Chong XJ; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
    Cancer Chemother Pharmacol; 2014 Feb; 73(2):381-8. PubMed ID: 24306119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
    Fukudo M; Ito T; Mizuno T; Shinsako K; Hatano E; Uemoto S; Kamba T; Yamasaki T; Ogawa O; Seno H; Chiba T; Matsubara K
    Clin Pharmacokinet; 2014 Feb; 53(2):185-96. PubMed ID: 24135988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
    Breaker K; Naam M; La Rosa FG; Flaig IP; Flaig TW
    Dermatol Surg; 2013 Jul; 39(7):981-7. PubMed ID: 23464361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
    Bednaríková D; Kocák I
    Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
    Shinohara N; Nonomura N; Eto M; Kimura G; Minami H; Tokunaga S; Naito S
    Ann Oncol; 2014 Feb; 25(2):472-6. PubMed ID: 24351402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
    Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
    Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitor induced pancreatitis.
    Sevin A; Chen A; Atkinson B
    J Oncol Pharm Pract; 2013 Sep; 19(3):257-60. PubMed ID: 23034406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
    Manchen E; Robert C; Porta C
    J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.